Clinical value of the Patient Global Assessment with Ankylosing Spondylitis: A cross-sectional study
- PMID: 38640261
- PMCID: PMC11030010
- DOI: 10.1097/MD.0000000000037791
Clinical value of the Patient Global Assessment with Ankylosing Spondylitis: A cross-sectional study
Abstract
To analyze the factors associated with the overall patient condition and explore the clinical value of the Patient Global Assessment (PGA) index for assessing the disease state in patients with Ankylosing Spondylitis (AS). This cross-sectional study used a standardized questionnaire to record the basic information of patients with AS. The collected data included the Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-reactive protein (CRP), ASDAS-erythrocyte sedimentation rate (ESR), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), PGA, and other clinical indicators. Statistical analysis was performed using SPSS 25.0 software, and the scale was assessed for retest reliability and structural validity. The Kruskal-Wallis H test and Spearman or Pearson correlation analysis were used to analyze the factors influencing PGA scores. The receiver operator characteristic (ROC) curve was used to identify the cutoff value of the PGA for predicting disease activity in AS. The patient age, disease duration, family history, and history of ocular inflammation significantly differed between PGA groups (P < .05). The median PGA was significantly lower in patients with disease remission than in those with disease activity (P < .01). The various clinical indexes significantly differed between PGA groups (P < .01). The PGA was significantly correlated with various clinical indicators (P < .01). The area under the ROC curve (AUC) for disease activity based on the ASDAS-CRP was 0.743 (P < .01) with a PGA cutoff value of 1.38; the AUC for disease activity based on the BASDAI was 0.715 (P < .01) with a PGA cutoff value of 1.63. The PGA was significantly correlated with patient-reported outcomes, disease activity, function, and psychological status, and may indicate the level of inflammation in patients with AS. A PGA of around 1.5 indicates disease activity.
Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
None of the authors has any conflicts of interest to declare.
Figures
References
-
- Dean LE, Jones GT, MacDonald AG, et al. . Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53:650–7. - PubMed
-
- Huang F, Zhu J, Wang YH, et al. . Diagnosis and treatment standards for ankylosing spondylitis. Chin J Intern Med. 2022;61:893–900. - PubMed
-
- Machado PM, Landewé R, Heijde DV; Assessment of SpondyloArthritis international Society (ASAS). Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77:1539–40. - PubMed
-
- van der Heijde D, Ramiro S, Landewé R, et al. . 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978–91. - PubMed
-
- Spoorenberg A, van Tubergen A, Landewé R, et al. . Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology (Oxford). 2005;44:789–95. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous